NCT04498689

Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer

Status unknown Phase 2 Last updated 4 August 2020

What this trial tests

Phase 2 trial testing Camrelizumab in Metastatic Pancreatic Cancer in 117 participants. Status unknown.

Timeline

1 August 2019

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	117
Start date	1 August 2019
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

• Camrelizumab — full drug profile →
• Nab paclitaxel
• Gemcitabine Injection

Conditions studied

• Metastatic Pancreatic Cancer — all drugs for Metastatic Pancreatic Cancer →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with Metastatic Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study is intended to investigate the objective response rate (ORR) and the progression-free survival (PFS) of the patients with histologically- or cytologically-confirmed metastatic pancreatic cancer after treating with the combination of camrelizumab, gemcitabine and nab-paclitaxel, and to investigate the overall survival (OS) and the adverse event (AE) of the patients with histologically- or cytologically-confirmed metastatic pancreatic cancer after treating with the combination of camrelizumab, gemcitabine and nab-paclitaxel.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review.
   Koltai T, Reshkin SJ, Carvalho TMA, Di Molfetta D, et al · · 2022 · cited 77× · PMID 35626089 · DOI 10.3390/cancers14102486
2. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy.
   Liu L, Huang X, Shi F, Song J, et al · · 2022 · cited 60× · PMID 35139879 · DOI 10.1186/s13046-022-02273-w
3. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies.
   Turpin A, Neuzillet C, Colle E, Dusetti N, et al · · 2022 · cited 20× · PMID 36090800 · DOI 10.1177/17588359221118019
4. Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer.
   Wandmacher AM, Letsch A, Sebens S. · · 2021 · cited 20× · PMID 34439389 · DOI 10.3390/cancers13164235
5. Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities.
   Arias-Pinilla GA, Modjtahedi H. · · 2021 · cited 18× · PMID 33917882 · DOI 10.3390/cancers13081781
6. Targeting Growth Factor Signaling Pathways in Pancreatic Cancer: Towards Inhibiting Chemoresistance.
   Xelwa N, Candy GP, Devar J, Omoshoro-Jones J, et al · · 2021 · cited 15× · PMID 34195085 · DOI 10.3389/fonc.2021.683788
7. Reshaping the Pancreatic Cancer Microenvironment at Different Stages with Chemotherapy.
   Peng M, Ying Y, Zhang Z, Liu L, et al · · 2023 · cited 10× · PMID 37173915 · DOI 10.3390/cancers15092448
8. B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy.
   Chen X, Li J, Chen Y, Que Z, et al · · 2022 · cited 3× · PMID 36499340 · DOI 10.3390/ijms232315005